Compare
Iqvia Holdings Inc. vs Icon PLC vs Incyte Corp vs Charles River Laboratories International, Inc.
| Latest fiscal year | Iqvia Holdings Inc. IQV | Icon PLC ICLR | Incyte Corp INCY | Charles River Laboratories International, Inc. CRL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-27 |
| Revenue | $16.31B | $8.25B | $5.14B | $4.02B |
| Revenue growth (YoY) | +5.9% | +0.8% | +21.2% | -0.9% |
| Gross margin | n/a | n/a | 92.8% (computed) | n/a |
| Operating margin | 13.4% | 5.4% | 29.5% | 0.6% |
| Net margin | 8.3% | 2.8% | 25.0% | -3.5% |
| Net income | $1.36B | $229.34M | $1.29B | -$142.16M |
| EPS (Diluted) | $7.84 | $2.90 | $6.41 | -$2.91 |
| Operating cash flow | $2.65B | $1.04B | $1.41B | $737.65M |
| Free cash flow | $2.05B | $861.99M | n/a | $518.49M |
| Cash & equivalents | $1.98B | $647.29M | $3.10B | $213.77M |
| Total assets | $29.94B | $16.27B | $6.96B | $7.14B |
| Total liabilities | $23.31B | $7.08B | $1.79B | $3.92B |
| Shareholders' equity | $6.63B | $9.19B | $5.17B | $3.17B |
| Return on year-end equity | 20.5% | 2.5% | 24.9% | -4.5% |
| Shares outstanding | 169.60M | 76.57M | 198.46M | 49.22M |
Revenue, most recent five fiscal years
| Fiscal year | Iqvia Holdings Inc. | Icon PLC | Incyte Corp | Charles River Laboratories International, Inc. |
|---|---|---|---|---|
| Latest | $16.31B Ended 2025-12-31 | $8.25B Ended 2025-12-31 | $5.14B Ended 2025-12-31 | $4.02B Ended 2025-12-27 |
| 1 year earlier | $15.40B Ended 2024-12-31 | $8.19B Ended 2024-12-31 | $4.24B Ended 2024-12-31 | $4.05B Ended 2024-12-28 |
| 2 years earlier | $14.98B Ended 2023-12-31 | $8.05B Ended 2023-12-31 | $3.70B Ended 2023-12-31 | $4.13B Ended 2023-12-30 |
| 3 years earlier | $14.41B Ended 2022-12-31 | $7.74B Ended 2022-12-31 | $3.39B Ended 2022-12-31 | $3.98B Ended 2022-12-31 |
| 4 years earlier | $13.87B Ended 2021-12-31 | $5.48B Ended 2021-12-31 | $2.99B Ended 2021-12-31 | $3.54B Ended 2021-12-25 |